Back
Viper Energy 10K Form
Buy
63
VNOM
Viper Energy
Last Price:
$44.25
Seasonality Move:
13.19%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-08 | 10Q | VNOM/Viper Energy Quarterly |
2023-08-03 | 10Q | VNOM/Viper Energy Quarterly |
2023-05-03 | 10Q | VNOM/Viper Energy Quarterly |
2022-11-08 | 10Q | VNOM/Viper Energy Quarterly |
2022-08-03 | 10Q | VNOM/Viper Energy Quarterly |
2022-05-05 | 10Q | VNOM/Viper Energy Quarterly |
Receive VNOM News And Ratings
See the #1 stock for the next 7 days that we like better than VNOM
VNOM Financial Statistics
Sales & Book Value
Annual Sales: | $859.7M |
---|---|
Cash Flow: | $-267.3M |
Price / Cash Flow: | 6.83 |
Annual Sales: | $16.38 |
Price / Book: | 3.44 |
Profitability
EPS (TTM): | 3.67000 |
---|---|
Net Income (TTM): | $359.2M |
Gross Margin: | $584.5M |
Return on Equity: | 11.34% |
Return on Assets: | 8.49% |
Viper Energy Earnings Forecast
Key Viper Energy Financial Ratios
-
The Gross Profit Margin over the past 12 years for VNOM is 67.98%.
-
The Selling, General & Administrative Expenses for VNOM have been equal to 2.17% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 20.56% of Operating Income.
-
The Net Earning history of VNOM is 41.78% of Total Revenues.
-
Per Share Earnings over the last 11 years have been positive in 7 years.
Viper Energy Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Oil, Gas & Consumable Fuels |
Sector: | Energy |
Current Symbol: | VNOM |
CUSIP: | 92763M |
Website: | viperenergy.com |
Debt
Debt-to-Equity Ratio: | 0.64 |
---|---|
Current Ratio: | 4.89 |
Quick Ratio: | 4.3 |
Price-to-Earnings
Trailing P/E Ratio: | 11.58 |
---|---|
Forward P/E Ratio: | 19.17 |
VNOM Technical Analysis vs Fundamental Analysis
Buy
63
Viper Energy (VNOM)
is a Buy
Is Viper Energy a Buy or a Sell?
-
Viper Energy stock is rated a BuyThe current Viper Energy [VNOM] share price is $44.23. The Score for VNOM is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.